Sponsor pipeline

Roche / Genentech clinical trial pipeline

Get alerts when Roche / Genentech's trials change

250 active trials 105 recruiting 89 Phase 3 10 disease areas 120 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days showing 50 of 120 changes on 20 trials

2026-08-22
Trial terminated
Trial terminated: The trial was terminated due to sponsor decision.
Enrollment reduced: 136 → 3 participants
Primary completion moved earlier: 2030-06-01 → 2026-06-24
Completion moved earlier: 2030-06-01 → 2026-06-24
NCT07214662 A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a… · Phase 1
2026-08-04
Trial status changed: Completed → Terminated
Trial terminated: Study was closed early as the sponsor decided not to continue development of certain treatment combinations.
NCT03869190 Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and… · Phase 1/2
2026-08-11
Trial status changed: Completed → Terminated
Trial terminated: The study was terminated prematurely by the Sponsor due to observation of dose-limiting adverse events meeting the prot...
NCT06961370 A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics… · Phase 1
2026-08-06
Withdrawn before enrolling
Trial withdrawn: Decision of Sponsor.
Enrollment reduced: 162 → 0 participants
NCT06984341 A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and… · Phase 1
2026-08-26
Primary completion pushed: 2026-06-30 → 2026-10-14
Completion pushed: 2026-06-30 → 2026-10-14
NCT04770896 A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone… · Phase 3
2026-08-15
Primary completion pushed: 2026-03-10 → 2026-08-25
NCT04567303 Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration · Phase 1/2
2026-07-30
Primary completion pushed: 2028-04-19 → 2029-12-03
Completion pushed: 2030-03-05 → 2030-05-30
NCT07234942 A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics… · Phase 1
2026-08-13
Primary endpoint(s) modified
Trial completed
NCT06106828 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of… · Phase 3
2026-08-01
Primary endpoint(s) modified
Trial completed
NCT05987423 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of… · Phase 3
2026-08-14
Primary endpoint(s) modified
Trial arms changed: 3 → 4
NCT05704361 A Study to Investigate the Safety, Tolerability, and Processing by the Body of… · Phase 1
2026-08-28
Enrollment reduced: 720 → 378 participants
Primary completion moved earlier: 2029-09-30 → 2026-10-31
Completion moved earlier: 2030-04-30 → 2026-11-28
NCT00781612 A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With… · Phase 2
2026-08-07
Enrollment reduced: 450 → 165 participants
Enrollment closed, study ongoing
Trial sites reduced: 41 → 36 locations
NCT05581004 A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single… · Phase 1
2026-07-31
Enrollment reduced: 113 → 85 participants
Trial completed
Primary completion moved earlier: 2026-09-30 → 2026-06-18
Completion moved earlier: 2026-09-30 → 2026-06-18
NCT04511845 A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid… · Phase 1
2026-08-14
Enrollment reduced: 1200 → 901 participants
Trial completed
Primary completion moved earlier: 2026-11-06 → 2026-03-18
Completion moved earlier: 2026-11-06 → 2026-03-18
NCT05872763 A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be…
2026-08-20
Phase changed: Phase 1/2 → Phase 3
Trial completed
NCT06624059 A Study to See How Well and How Safely Different Treatments Work in a Group of… · Phase 3
2026-08-21
Enrollment reopened
Trial sites expanded: 25 → 34 locations
NCT04910568 A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in… · Phase 1
2026-08-20
Recruitment opened
Trial sites expanded: 0 → 5 locations
NCT07617337 AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer · Phase 1
2026-08-15
Enrollment closed, study ongoing
Trial sites reduced: 486 → 481 locations
Primary completion moved earlier: 2034-07-01 → 2027-06-30
Completion moved earlier: 2034-07-01 → 2027-06-30
NCT05878769 A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic… · Phase 3
2026-08-15
Enrollment closed, study ongoing
Trial sites reduced: 204 → 178 locations
NCT05797610 A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants… · Phase 3
2026-08-11
Recruitment opened
NCT07541170 A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's… · Phase 3

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-08-24 NCT07781644 Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease Phase 1/2 Not Yet Recruiting
2026-08-24 NCT07781657 Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease Phase 2 Not Yet Recruiting
2026-08-24 NCT07783009 An Expanded Access Program to Provide Divarasib to Participants With Previously Treated… Available
2026-08-06 NCT07749157 A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple… Phase 1 Not Yet Recruiting
2026-08-05 NCT07748208 A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib… Phase 2 Not Yet Recruiting
2026-08-03 NCT07741604 A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in… Phase 1 Not Yet Recruiting

Active trials by phase

Phase 1
52
Phase 1/2
27
Phase 2
53
Phase 2/3
4
Phase 3
85
Phase 4
10
Not charted: 19 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 250

NCT IDTitleConditionStatusUpdated
Phase 4
NCT07609719 A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple… Multiple Sclerosis Recruiting 2026-08-13
NCT05861999 A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric… Muscular Atrophy, Spinal Recruiting 2026-08-11
NCT04853251 A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related… Neovascular Age-related Macular Degeneration Recruiting 2026-08-10
NCT06274515 A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies Breast Cancer Recruiting 2026-08-06
NCT05861986 A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early… Muscular Atrophy, Spinal Recruiting 2026-08-04
NCT05224102 A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented… Diabetic Macular Edema Active, Not Recruiting 2026-08-25
NCT06795048 A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants… Neovascular Age-related Macular Degeneration (nAMD) Active, Not Recruiting 2026-07-31
NCT05181618 A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants… Severe Hemophilia A Active, Not Recruiting 2026-07-27
NCT05232929 Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA) Spinal Muscular Atrophy Active, Not Recruiting 2026-07-16
NCT07483450 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of… Relapsing Multiple Sclerosis Active, Not Recruiting 2026-07-06
Phase 3
NCT05894239 A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo… Metastatic Breast Cancer Recruiting 2026-08-25
NCT06847542 A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD Neovascular Age-related Macular Degeneration Recruiting 2026-08-21
NCT07177352 Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's… Alzheimers Disease Recruiting 2026-08-21
NCT06819878 A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With… Moderately to Severely Active Crohns Disease Recruiting 2026-08-20
NCT07541079 A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant… Early Breast Cancer Recruiting 2026-08-17
NCT07158242 A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121)… Moderately to Severely Active Ulcerative Colitis Recruiting 2026-08-14
NCT07351045 A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With… Obesity or Overweight Recruiting 2026-08-14
NCT07351058 A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With… Obesity or Overweight Recruiting 2026-08-14
NCT07555938 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… Multiple Myeloma Recruiting 2026-08-14
NCT07670416 A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or… Obesity Recruiting 2026-08-13
NCT05199688 A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And… Neuromyelitis Optica Spectrum Disorder Recruiting 2026-08-11
NCT05862285 A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La… Cancer Recruiting 2026-08-10
NCT06998524 A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von… Von Willebrand Disease, Type 3 Recruiting 2026-08-10
NCT07298421 A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for… Moderately to Severely Active Crohns Disease Recruiting 2026-08-10
NCT07541170 A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's… Non-small Cell Lung Cancer Recruiting 2026-08-10
See all 250 active Roche / Genentech trials with filters →

Disease areas by active trials

Breast Cancer (28) · Multiple Sclerosis (23) · Non-Small Cell Lung Cancer (NSCLC) (18) · Lung Cancer (17) · Liver Cancer (8) · Alzheimer's Disease (8) · Multiple Myeloma (8) · Obesity (8) · Colorectal Cancer (6) · Lupus (SLE) (6)

Get alerts when Roche / Genentech's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free